Obiettivo Cancer is not only a leading public health challenge in Europe, it is also a growing economic challenge. Over three million cases are currently diagnosed each year across the continent. Forecasts show that by 2020 almost half of the population will be diagnosed with the disease in their lifetime. The cost of cancer for the EU is €126 billion per year and rising. The health and economic implications of cancer therefore provide a compelling business opportunity for technologies that can improve health outcomes and reduce treatment costs. Surgery remains one of the primary treatments for cancer, yet surgeons lack the tools to identify accurately and remove cancer during an operation, resulting in costly re-operations and negative health ramifications. Lightpoint Medical has developed a molecular imaging camera (LightPath™) based on a breakthrough imaging modality, Cerenkov Luminescence Imaging (CLI). The technology can provide surgeons with real time intraoperative analysis of cancerous tissue to ensure the complete removal of cancer in a single operation. The device provides the potential for a dramatic reduction in costly re-operations and adjuvant therapies across a wide range of major cancer indications, proving not only an innovative solution for healthcare providers, but also a tool to substantially reduce cancer care costs.CerISMA is proposed as a multi-centre clinical trial to confirm the clinical efficacy of LightPath™ in a lead cancer indication and to evidence the health economic impact of the technology. The project is vital for the company’s growth, fundamentally underpinning the company’s ambitious sales and marketing strategy across strategic target territories in Europe and the US. Campo scientifico medical and health sciencesclinical medicineoncologyprostate cancermedical and health sciencesclinical medicinesurgerymedical and health sciencesclinical medicineradiologynuclear medicinemedical and health sciencesclinical medicineoncologybreast cancermedical and health sciencesclinical medicineoncologyhead and neck cancer Programma(i) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.2.1.3. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials H2020-EU.3.1.3. - Treating and managing disease Argomento(i) PHC-12-2015 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Invito a presentare proposte H2020-SMEInst-2014-2015 Vedi altri progetti per questo bando Bando secondario H2020-SMEINST-2-2015 Meccanismo di finanziamento SME-2 - SME instrument phase 2 Coordinatore LIGHTPOINT MEDICAL LTD Contribution nette de l'UE € 2 351 461,25 Indirizzo MISBOURNE WORKS WATERSIDE HP5 1PE CHESHAM Regno Unito Mostra sulla mappa PMI L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione. Sì Regione South East (England) Berkshire, Buckinghamshire and Oxfordshire Buckinghamshire CC Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Collegamenti Contatta l’organizzazione Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 2 351 461,25
